Therapy for Severe Psoriasis

Author
By Jashin J. Wu, MD, FAAD, Steven R. Feldman, MD, PhD and Mark G. Lebwohl, M.D., Ph.D.
ISBN
9780323447973
Publication Date
30-11-2016
Learn More
Hardback
$99.99 $89.99
+ WishList
  • Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab.
  • Takes an evidence-based approach to hard-to-treat severe psoriasis.
  • Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text.
  • Presents combination approaches for instances when standard treatments are not successful.
  • Includes an overview chapter to help beginners understand the nuances of the disorder.
  • Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, images, and references from the book on a variety of devices.

A brand-new title in the field of dermatology, Therapy for Severe Psoriasis provides the ultimate coverage of the treatment options available for today's most serious cases, including biologics and oral therapies. It features discussions of the newest drug therapies, recent FDA-approved biosimilars, and combination approaches to care, while an overview chapter was designed to aid those new to the field in understanding the nuances of difficult-to-treat subtypes of psoriasis. Comprehensive and focused, Therapy for Severe Psoriasis will be a welcome addition to the library of any dermatologist seeking in-depth information on the challenges of this condition.


Key Features
  • Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab.
  • Takes an evidence-based approach to hard-to-treat severe psoriasis.
  • Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text.
  • Presents combination approaches for instances when standard treatments are not successful.
  • Includes an overview chapter to help beginners understand the nuances of the disorder.
  • Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, images, and references from the book on a variety of devices.
ADDITIONAL INFORMATION
ISBN 9780323447973
Author Informaiton By Jashin J. Wu, MD, FAAD, Director of Dermatology Research, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA ; Steven R. Feldman, MD, PhD, Professor of Dermatology, Departments of Dermatology, Pathology and Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA and Mark G. Lebwohl, M.D., Ph.D., Professor and Chair, Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Pp Authortext Wu, Feldman & Lebwohl
Published Reviews

"gives a fine overview of the treatments available for patients with moderate to severe psoriasis"

"Therapy for Severe Psoriasis can serve as your go-to resource for a comprehensive understanding of therapies that are currently available."

"This is a useful reference for staying current on how to use biologics and other new drugs for severe psoriasis."

- Patricia Wong, MD (Private Practice) for Doody's Review Services

E-SBN 9780323447980
Imprint Elsevier
Publication Date 30-11-2016
Pages 202
Trim 229 x 152 (6 x 9)
Write Your Own Review
Only registered users can write reviews. Please Sign in or create an account

Back to top